/images/ppid_59c68470-image-177082256615070290.webp)
/images/ppid_a911dc6a-image-177082162155797346.webp)
/images/ppid_a911dc6a-image-177082165123413151.webp)
/images/ppid_a911dc6a-image-177082108678283570.webp)
What is the story about?
AstraZeneca Pharma India reported a sharp 39% year-on-year rise in revenue for the quarter ended December 2025, supported by consistent performance across its core therapy areas, even as profitability metrics weakened.
Revenue for Q3 FY26 stood at ₹611.5 crore compared with ₹440.2 crore in the year-ago period. Net profit rose 5.9% to ₹32.6 crore from ₹30.8 crore last year.
However, operating performance came under pressure. EBITDA declined 41.7% year-on-year to ₹44.8 crore from ₹76.9 crore, while the EBITDA margin contracted to 7.3% from 17.5% a year earlier.
The company attributed its topline growth to sustained momentum across Oncology, Biopharmaceuticals — including cardiovascular, renal and metabolism (CVRM), respiratory and immunology (R&I), vaccines and immune therapies (V&I) — as well as Rare Disease segments.
Over the past nine months of FY26, AstraZeneca received eight new regulatory approvals for medicines or new indications, strengthening its portfolio in India.
Bhavana Agrawal, Chief Financial Officer and Director, said the performance reflected “steady, portfolio-driven growth driven by disciplined execution,” adding that the company continues to see consistent momentum as its medicines reach more patients.
Also Read: Mrs Bectors Q3 Results: Shares slip nearly 4% despite profit growth; dividend declared
Country President and Managing Director Praveen Akkinepally said the quarter underscored AstraZeneca’s “commitment to growth through innovation” and its science-led strategy in India.
Ahead of the results, shares of AstraZeneca Pharma India closed at ₹9,070.80, up 1.3% on the NSE.
Revenue for Q3 FY26 stood at ₹611.5 crore compared with ₹440.2 crore in the year-ago period. Net profit rose 5.9% to ₹32.6 crore from ₹30.8 crore last year.
However, operating performance came under pressure. EBITDA declined 41.7% year-on-year to ₹44.8 crore from ₹76.9 crore, while the EBITDA margin contracted to 7.3% from 17.5% a year earlier.
The company attributed its topline growth to sustained momentum across Oncology, Biopharmaceuticals — including cardiovascular, renal and metabolism (CVRM), respiratory and immunology (R&I), vaccines and immune therapies (V&I) — as well as Rare Disease segments.
Over the past nine months of FY26, AstraZeneca received eight new regulatory approvals for medicines or new indications, strengthening its portfolio in India.
Bhavana Agrawal, Chief Financial Officer and Director, said the performance reflected “steady, portfolio-driven growth driven by disciplined execution,” adding that the company continues to see consistent momentum as its medicines reach more patients.
Also Read: Mrs Bectors Q3 Results: Shares slip nearly 4% despite profit growth; dividend declared
Country President and Managing Director Praveen Akkinepally said the quarter underscored AstraZeneca’s “commitment to growth through innovation” and its science-led strategy in India.
Ahead of the results, shares of AstraZeneca Pharma India closed at ₹9,070.80, up 1.3% on the NSE.
/images/ppid_59c68470-image-177082252977485298.webp)
/images/ppid_59c68470-image-177082253958777729.webp)
/images/ppid_59c68470-image-177082253393829449.webp)
